CN112353928A

CN112353928A - Pharmaceutical composition for relieving osteoporotic thoracolumbar vertebral fracture

Info

Publication number: CN112353928A
Application number: CN202011451880.6A
Authority: CN
Inventors: 崔海波; 覃海滨
Original assignee: Shimen County Hospital Of Traditional Chinese Medicine
Current assignee: Shimen County Hospital Of Traditional Chinese Medicine
Priority date: 2020-12-10
Filing date: 2020-12-10
Publication date: 2021-02-12

Abstract

The invention relates to the technical field of traditional Chinese medicines, in particular to a traditional Chinese medicine composition for relieving osteoporotic thoracolumbar vertebral fracture, which is prepared from the following raw materials of active ingredients in parts by mass: 3-10 parts of cassia twig, 3-30 parts of borneol, 3-10 parts of garden balsam stem, 3-10 parts of galangal, 2-6 parts of notopterygium root, 3-10 parts of radix angelicae pubescentis, 2-6 parts of camphor, 2-6 parts of siegesbeckia orientalis, 1.5-5 parts of prepared radix aconiti, 2-6 parts of rhizoma sparganii, 2-6 parts of curcuma zedoary, 2-6 parts of sappan wood, 2-10 parts of lycopodium clavatum, 2-6 parts of herba lycopi, 5-10 parts of radix clematidis, 1-5 parts of asarum and 1-5 parts of prepared kusnezoff monkshood root.

Description

Pharmaceutical composition for relieving osteoporotic thoracolumbar vertebral fracture

Technical Field

The invention relates to the technical field of traditional Chinese medicines, and in particular relates to a pharmaceutical composition for relieving osteoporotic thoracolumbar vertebral fracture.

Background

For kidney qi heat, the lumbar and spinal regions are dry and marrow is reduced, resulting in atrophy of bone. The osteoporotic thoracolumbar fracture is a common senile disease and frequently encountered disease of the family I, and a large number of outpatients and inpatients are available in each month.

The traditional Chinese medicine category of bone atrophy belongs to kidney deficiency, bone erosion, deep rooted carbuncle and the like, the symptoms similar to the disease are recorded in Huangdi's classic, and the cloud' kidney qi heat in the book can lead to failure of the waist and the spine, bone withering and marrow reduction, and the bone atrophy is generated. The term "the lower Jing" (ancient Lai Jing) says that the wet land is also the cause of flaccidity of meat. Over-exertion, thirst with severe heat, yang qi depressing internally, heat in the kidney during internal depressing, water in the kidney and fire in the present day, bone exhaustion and marrow deficiency, so it is known as flaccidity of bone. Modern medicine is classified as osteoporosis, which is a systemic bone disease in which bone fragility is increased and fracture is likely to occur due to a decrease in bone mass caused by various reasons. Clinically, the pain of the waist and the back is difficult to endure, the patient cannot turn over or get up or down, even loud speech, slight cough and deep breathing induce severe pain, and the life is seriously affected. For such patients, the patients should be treated as early as possible and an effective treatment method should be adopted to relieve the clinical symptoms of the patients as soon as possible.

Disclosure of Invention

The invention aims to provide a pharmaceutical composition for relieving osteoporotic thoracolumbar vertebral fracture.

In order to solve the technical problems, the invention provides a pharmaceutical composition for relieving osteoporotic thoracolumbar fractures, which is prepared from the following raw materials of active ingredients in parts by mass: 3-10 parts of cassia twig, 3-30 parts of borneol, 3-10 parts of garden balsam stem, 3-10 parts of galangal, 2-6 parts of notopterygium root, 3-10 parts of radix angelicae pubescentis, 2-6 parts of camphor, 2-6 parts of siegesbeckia orientalis, 1.5-5 parts of prepared monkshood, 2-6 parts of rhizoma sparganii, 2-6 parts of curcuma zedoary, 2-6 parts of sappan wood, 2-10 parts of lycopodium clavatum, 2-6 parts of herba lycopi, 5-10 parts of radix clematidis, 1-5 parts of asarum, 4-10 parts of rhizoma curcumae longae and 1-5 parts of prepared kusne.

Preferably, the raw materials for preparing the active ingredients of the traditional Chinese medicine composition consist of the following traditional Chinese medicinal materials in parts by mass: 10 parts of cassia twig, 30 parts of borneol, 10 parts of garden balsam stem, 10 parts of galangal, 6 parts of notopterygium root, 10 parts of radix angelicae pubescentis, 6 parts of camphor, 6 parts of herba siegesbeckiae, 5 parts of prepared radix aconiti, 6 parts of rhizoma sparganii, 6 parts of curcuma zedoary, 6 parts of sappan wood, 10 parts of lycopodium clavatum, 6 parts of herba lycopi, 10 parts of radix clematidis, 5 parts of asarum, 10 parts of rhizoma curcumae longae and 5 parts of prepared radix aconiti.

The application of the pharmaceutical composition in preparing any one of the following medicines:

1) a medicine for relieving osteoporotic thoracolumbar fracture;

2) a medicine for relieving the pain of the osteoporotic thoracolumbar fracture;

3) the medicine for relieving osteoporotic thoracolumbar fracture and edema.

The invention has the beneficial effects that: the prescription of the invention has unique composition, when in use, the components are ground into powder and decocted into medicinal liquid for fumigation, thus relieving the osteoporotic thoracolumbar vertebral fracture and relieving the pain and edema of the osteoporotic thoracolumbar vertebral fracture and having good treatment effect.

Detailed Description

The present invention will be described in further detail with reference to examples.

Example one

A pharmaceutical composition for relieving osteoporotic thoracolumbar fracture comprises the following raw materials of active ingredients in parts by mass: 3 parts of cassia twig, 3 parts of borneol, 3 parts of garden balsam stem, 3 parts of galangal, 2 parts of notopterygium root, 3 parts of pubescent angelica root, 2 parts of camphor, 2 parts of siegesbeckia orientalis, 1.5 parts of prepared common monkshood mother root, 2 parts of common burreed rhizome, 2 parts of zedoary, 2 parts of sappan wood, 2 parts of common clubmoss herb, 2 parts of hiraute shiny bugleweed herb, 5 parts of clematis root, 1 part of asarum and 1 part of prepared kusne.

When in use, the medicines are pulverized, the decocting machine is decocted for 30 minutes, the decoction is taken and applied to a traditional Chinese medicine fumigation and washing therapeutic apparatus (four limbs style) for traditional Chinese medicine fumigation and washing treatment, 25 minutes each time, 1 time every day, and 7 times of 1 course.

Example two

A pharmaceutical composition for relieving osteoporotic thoracolumbar fracture comprises the following raw materials of active ingredients in parts by mass: 5 parts of cassia twig, 6 parts of borneol, 6 parts of garden balsam stem, 6 parts of galangal, 4 parts of notopterygium root, 5 parts of pubescent angelica root, 3 parts of camphor, 3 parts of siegesbeckia orientalis, 2 parts of prepared common monkshood mother root, 3 parts of common burreed rhizome, 3 parts of zedoary, 3 parts of sappan wood, 3 parts of common clubmoss herb, 3 parts of hiraute shiny bugleweed herb, 6 parts of clematis root, 2 parts of asarum and 2 parts of prepared kusne.

EXAMPLE III

A pharmaceutical composition for relieving osteoporotic thoracolumbar fracture comprises the following raw materials of active ingredients in parts by mass: 10 parts of cassia twig, 30 parts of borneol, 10 parts of garden balsam stem, 10 parts of galangal, 6 parts of notopterygium root, 10 parts of radix angelicae pubescentis, 6 parts of camphor, 6 parts of herba siegesbeckiae, 5 parts of prepared radix aconiti, 6 parts of rhizoma sparganii, 6 parts of curcuma zedoary, 6 parts of sappan wood, 10 parts of lycopodium clavatum, 6 parts of herba lycopi, 10 parts of radix clematidis, 5 parts of asarum and 5 parts of prepared radix aconiti agrestis.

In order to show the curative effect of the medicine, the following clinical comparative tests are carried out.

1.1 clinical data 32 osteoporotic thoracolumbar vertebral fracture patients admitted to the hospital 6 in 2019 to 2020 were selected as study subjects and randomly divided into an observation group and a control group, 16 cases each. The comparison of the basic data of age, sex, disease course, pain degree and difficulty in life of the two groups has no statistical significance and is comparable. The study was approved by the hospital ethics committee.

Inclusion criteria were: the patients meet the diagnosis standard of the flaccid bone diseases in the 'standard of curative effect for diagnosing traditional Chinese medicine symptoms' issued by the State administration of traditional Chinese medicine in 2010; there is pain at the fracture site and limited movement of the corresponding spine; the age is greater than 60 years; spinal MRI examination revealed corresponding vertebral body compressibility changes and bone marrow edema; the clinical data is complete; no related medication contraindications; all gave informed consent to the study and voluntarily signed the informed consent.

Exclusion criteria: mental illness, confusion, communication impairment; patients with severe cardiovascular and cerebrovascular diseases and diabetes with poor blood sugar control (fasting more than 8.0 mmol/L); those who are unable to tolerate the treatment modalities of this study; patients with severe visceral disorders; family members or patients with poor treatment compliance.

1.2 methods

Control group: adopts western medicine for calcium supplement, metabolism regulation, anti-inflammatory and analgesic treatment. The patient lies on the hardboard bed for rest in the acute stage, the waist and dorsal muscle function exercise is carried out after the pain is relieved, and the patient wears the waistline when getting out of bed for activity.

Observation group: local external fumigation is carried out by using the combined self-made fumigation and washing powder on the basis of the treatment of a control group. The medicine composition is as follows: 10g of cassia twig, 30g of borneol, 10g of garden balsam stem, 10g of galangal, 6g of notopterygium root, 10g of pubescent angelica root, 6g of camphor, 6g of siegesbeckia orientalis, 5g of prepared common monkshood mother root, 6g of common burreed rhizome, 6g of zedoary, 6g of sappan wood, 10g of common clubmoss herb, 6g of hiraute shiny bugleweed herb, 10g of clematis root, 5g of asarum and 5g of prepared kusnezoff monkshood root, wherein the medicines are pulverized in a traditional Chinese medicine processing room of the hospital, and a decocting machine is used for decocting for 30 minutes to obtain a medicinal liquid which is used for carrying out traditional Chinese.

Two groups of patients were compared for pain VAS scores before and after treatment and days of hospitalization to restore self-care ability. The VAS score evaluation times were pre-treatment, 1 week post-treatment, and pre-discharge, respectively. And counting the number of hospitalization days of the patient.

And (3) healing: the pain of the chest, the waist and the back disappears, the pitching movement of the turning side is not limited, and the normal life is recovered. The method has the following advantages: the pain of the chest, the waist and the back is obviously relieved, and the pitching movement of the turning side is painful and can be tolerated. And (4) invalidation: the pain of the chest, waist and back is relieved, and the pain can not be endured when the patient turns to the side and moves in a pitching way.

1.4 statistical methods

SPSS 19.0 statistical software is used for data analysis, the measured data is expressed in x +/-s, and the comparison adopts t test, and the difference of P less than 0.05 has statistical significance.

2. Results

2.11 weeks effective rate

The experimental results show that the effective rate (recovery + effective) of the observation group patients after 1 week is 13 (81.25%), the effective rate (recovery + effective) of the control group patients after 1 week is 11 (68.75%), the effective rate of the observation group patients after 1 week is obviously superior to that of the control group, and the difference between the groups has statistical significance (P is less than 0.01). See Table 1 for details

TABLE 1 comparison of effective rates after two 1 treatment courses

Group of	Recovery method	Is effective	Invalidation	1 course of treatment has obvious effect
					Observation group (n ═ 16)	3	10	3	81.25％
Observation group (n ═ 16)	2	9	5	68.75％

2.2 recovery Rate and Total effective Rate at discharge

The experimental result shows that the cure rate of the patients in the observation group at the time of discharge is 12 (75%), and the cure rate of the patients in the control group at the time of discharge is 8 (50%); the total effective rate (recovery + effective) of the patients in the observation group at the time of discharge is 16 (100%), the total effective rate (recovery + effective) of the patients in the control group at the time of discharge is 14 (87.5%), and the differences among the groups have obvious statistical significance (P is less than 0.01) when the recovery rates and the total effective rates of the patients in the observation group at the time of discharge are compared with those of the control group. Table 2 for details of the comparison of two groups of total effective rates

Group of	Recovery method	Is effective	Invalidation	Rate of recovery	Total effective rate
						Observation group (n ═ 16)	12	4	0	75％	100％
Control group (n ═ 16)	8	6	2	50％	87.5％

2.3 average days of hospitalization

The experimental results show that the average number of hospitalizations of the patients in the observation group is (10.7 +/-1.4) days, the average number of hospitalizations of the patients in the control group is (13.5 +/-2.1) days, the average number of hospitalizations of the patients in the observation group is obviously less than that of the patients in the control group, and the difference between the groups has statistical significance (P < 0.05). See Table 3 for details

TABLE 3 comparison of average days in hospital

Group of	Average number of days in hospital (day)
		Observation group (n ═ 16)	10.7±1.4
Control group (n ═ 16)	13.5±2.1

The above description is only a preferred embodiment of the present invention, and for those skilled in the art, the present invention should not be limited by the description of the present invention, which should be interpreted as a limitation.

Claims

1. The traditional Chinese medicine composition for relieving osteoporotic thoracolumbar fracture is characterized in that raw materials for preparing active ingredients of the traditional Chinese medicine composition consist of the following traditional Chinese medicinal materials in parts by mass: 3-10 parts of cassia twig, 3-30 parts of borneol, 3-10 parts of garden balsam stem, 3-10 parts of galangal, 2-6 parts of notopterygium root, 3-10 parts of radix angelicae pubescentis, 2-6 parts of camphor, 2-6 parts of siegesbeckia orientalis, 1.5-5 parts of prepared monkshood, 2-6 parts of rhizoma sparganii, 2-6 parts of curcuma zedoary, 2-6 parts of sappan wood, 2-10 parts of lycopodium clavatum, 2-6 parts of herba lycopi, 5-10 parts of radix clematidis, 1-5 parts of asarum and 1-5 parts of prepared kusnezoff monkshoo.

2. The traditional Chinese medicine composition for relieving osteoporotic thoracolumbar vertebral fracture as claimed in claim 1, wherein raw materials for preparing active ingredients of the traditional Chinese medicine composition are composed of the following traditional Chinese medicinal materials in parts by mass: 10 parts of cassia twig, 30 parts of borneol, 10 parts of garden balsam stem, 10 parts of galangal, 6 parts of notopterygium root, 10 parts of radix angelicae pubescentis, 6 parts of camphor, 6 parts of herba siegesbeckiae, 5 parts of prepared radix aconiti, 6 parts of rhizoma sparganii, 6 parts of curcuma zedoary, 6 parts of sappan wood, 10 parts of lycopodium clavatum, 6 parts of herba lycopi, 10 parts of radix clematidis, 5 parts of asarum and 5 parts of prepared radix aconiti agrestis.

3. Use of a pharmaceutical composition according to claim 1 or 2 for the preparation of any one of the following:

1) a medicine for treating osteoporotic thoracolumbar fracture;

2) the medicine for relieving the pain of the osteoporotic thoracolumbar fracture.